Resonance Health Limited

RHT.ASX

Health Care

Health Care Equipment & Services

Market Data

Price

$0.041

+0.0%
Market Cap

$19.6M

P/E Ratio

27.5x

EPS

$0.001

Div. Yield

0.00%

52-Week Change

-0.1%

Latest Earnings

Half Year Results

27 February 2026

Revenue
$8.00
+53.0% YoY
NPAT
$1.50

Resonance Health (ASX: RHT) delivered a strong 1H FY26 result, with revenue surging 53% to $8M and a return to profitability with net profit after tax of $1.5M (vs. a $1.0M loss in 1H FY25). Growth was driven across all three business units — Resonance Clinical, TrialsWest, and SaMD — with Normalised EBITDA of $1.6M at a 20% operating margin. Full-year FY26 guidance of $17M revenue and $2M EBITDA was maintained, underpinned by a record SaMD pipeline exceeding $10M and continued clinical trial execution. Key points: Revenue grew 53% to $8M (1H FY25: $5.27M), a record half-year result; Returned to profitability with NPAT of $1.5M vs. a $1.0M loss in the prior corresponding period; Normalised EBITDA of $1.6M at a healthy 20% operating margin

Recent Announcements

27 Feb 2026 Supplementary Positive

Half Year Results Presentation

Resonance Health reported 1H FY26 results showing 53% revenue growth to $8.0M, normalised EBITDA of $1.6M (20% margin), and a profit after tax of $1.5M, with the company maintaining full-year FY26 guidance of ~$17M revenue and $2M EBITDA.

27 Feb 2026 Actual Results Positive

Half Year Results

Resonance Health (ASX: RHT) delivered a strong 1H FY26 result, with revenue surging 53% to $8M and a return to profitability with net profit after tax of $1.5M (vs. a $1.0M loss in 1H FY25). Growth was driven across all three business units — Resonance Clinical, TrialsWest, and SaMD — with Normalised EBITDA of $1.6M at a 20% operating margin. Full-year FY26 guidance of $17M revenue and $2M EBITDA was maintained, underpinned by a record SaMD pipeline exceeding $10M and continued clinical trial execution. Key points: Revenue grew 53% to $8M (1H FY25: $5.27M), a record half-year result; Returned to profitability with NPAT of $1.5M vs. a $1.0M loss in the prior corresponding period; Normalised EBITDA of $1.6M at a healthy 20% operating margin

Get real-time alerts for RHT

Receive AI-powered earnings summaries and instant notifications when Resonance Health Limited releases results.

Register Free